Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting

Results from Two Pivotal Phase 3 Clinical Trials of Lead Candidate VP-102 in the Treatment of Molluscum Contagiosum to be Presented on March 2, 2019

WEST CHESTER, Pa., Feb. 12, 2019 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced that results from two pivotal Phase 3 clinical trials of its lead product candidate, VP-102, will be presented in a late-breaking oral presentation during the annual meeting of the American Academy of Dermatology (AAD) being held March 1-5, 2019 in Washington, DC.

VP-102 is a proprietary topical drug-device combination therapy in development for the treatment of molluscum contagiosum, a highly contagious, primarily pediatric, viral skin infection that affects an estimated six million people in the United States, and for which there is currently no FDA-approved treatment.

The presentation, “CAMP-1 (Cantharidin Application in Molluscum Patients) and CAMP-2: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Studies Investigating VP-102, a Drug-Device Combination Containing a Novel Topical Formulation of Cantharidin, for the Treatment of Molluscum Contagiosum,” will take place during the Late-Breaking Research: Clinical Studies/Pediatric Session on Saturday, March 2 from 3:30-5:30 p.m. in Room 154A. The results will be presented by lead investigator, Dr. Lawrence F. Eichenfield, Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego.

The CAMP-1 and CAMP-2 studies enrolled 528 patients in total and were conducted at 31 centers in the United States. The trials evaluated the safety and efficacy of VP-102 compared to placebo in patients two years of age and older with molluscum contagiosum. Complete clearance of molluscum lesions was evaluated by assessment of the number of lesions at study visits over 12 weeks.

Verrica will also present an abstract from its Phase 2 Innovate study in an online e-poster titled “Innovate: A Phase 2 Study Investigating VP-102, a Drug-Device Combination Containing a Novel Topical Formulation of Cantharidin, for the Treatment of Molluscum Contagiosum.”

About VP-102
Verrica is currently advancing its lead product VP-102, a proprietary topical drug-device combination therapy containing a topical solution of 0.7% cantharidin in a novel, single-use applicator, for the treatment of molluscum contagiosum, verruca vulgaris (common warts), and external genital warts.

About Molluscum Contagiosum
Molluscum contagiosum, or molluscum, is a highly contagious, primarily pediatric, viral skin infection affecting an estimated six million people in the United States. It is caused by a pox virus that produces multiple raised flesh-colored papules, or skin lesions. Molluscum typically presents with 10 to 30 lesions, and in some cases over 100 lesions. If left untreated, molluscum lesions persist for an average of 13 months with some cases remaining unresolved for more than two years. There are currently no FDA-approved drugs for molluscum.

About Verrica Pharmaceuticals Inc.
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. Verrica is headquartered in West Chester, PA. For more information, please visit www.verrica.com.